Abstract | OBJECTIVE: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. We report final results of SELECTED. METHODS: Eligible participants who completed 1-2 years of daclizumab beta treatment in SELECT/SELECTION received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years in SELECTED. Safety assessments were evaluated for the SELECTED treatment period; efficacy data were evaluated from first dose of daclizumab beta in SELECT/SELECTION. RESULTS: Ninety percent (410/455) of participants who completed treatment in SELECTION enrolled in SELECTED. Within SELECTED, 69% of participants received daclizumab beta for > 3 years, 39% for > 4 years, and 9% for > 5 years; 87% of participants experienced an adverse event and 26% a serious adverse event (excluding multiple sclerosis relapse). No deaths occurred. Overall, hepatic events were reported in 25% of participants; serious hepatic events in 2%. There were no confirmed cases of immune-mediated encephalitis. Based on weeks from the first daclizumab beta dose in SELECT/SELECTION, adjusted annualized relapse rate (95% confidence interval) for weeks 0-24 was 0.21 (0.16-0.29) and remained low on continued treatment. Overall incidence of 24-week confirmed disability progression was 17.4%. Mean numbers of new/newly enlarging T2 hyperintense lesions remained low; percentage change in whole brain volume decreased over time. CONCLUSIONS: The effects of daclizumab beta on clinical and radiologic outcomes were sustained for up to ~ 8 years of treatment. No new safety concerns were identified in SELECTED. TRIAL REGISTRATION: Clinicaltrials.gov NCT01051349; first registered on January 15, 2010.
|
Authors | Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Kubala Havrdova, Xavier Montalban, Dusan Stefoski, Till Sprenger, Randy R Robinson, Sami Fam, Jonathan Smith, Spyros Chalkias, Giorgio Giannattasio, Gabriel Lima, Wanda Castro-Borrero |
Journal | Journal of neurology
(J Neurol)
Vol. 267
Issue 10
Pg. 2851-2864
(Oct 2020)
ISSN: 1432-1459 [Electronic] Germany |
PMID | 32451615
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Immunoglobulin G
- Immunosuppressive Agents
- Daclizumab
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
- Daclizumab
(adverse effects, therapeutic use)
- Female
- Humans
- Immunoglobulin G
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Male
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy)
|